Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRX NASDAQ:COLL NASDAQ:NATR NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/ACOLLCollegium Pharmaceutical$34.41-0.7%$35.65$23.23▼$42.29$1.08B0.63439,255 shs291,105 shsNATRNature's Sunshine Products$15.89-2.2%$16.18$11.01▼$18.06$280.30M1.1199,082 shs48,031 shsSAVACassava Sciences$2.99-3.5%$2.33$1.15▼$33.98$144.45M-2.064.22 million shs2.71 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRXChimerix0.00%0.00%0.00%0.00%+856.97%COLLCollegium Pharmaceutical0.00%-3.75%-11.31%+16.37%-10.06%NATRNature's Sunshine Products0.00%-1.73%-5.70%+7.44%+13.18%SAVACassava Sciences0.00%+31.14%+31.14%+65.19%-89.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/ACOLLCollegium Pharmaceutical$34.41-0.7%$35.65$23.23▼$42.29$1.08B0.63439,255 shs291,105 shsNATRNature's Sunshine Products$15.89-2.2%$16.18$11.01▼$18.06$280.30M1.1199,082 shs48,031 shsSAVACassava Sciences$2.99-3.5%$2.33$1.15▼$33.98$144.45M-2.064.22 million shs2.71 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRXChimerix0.00%0.00%0.00%0.00%+856.97%COLLCollegium Pharmaceutical0.00%-3.75%-11.31%+16.37%-10.06%NATRNature's Sunshine Products0.00%-1.73%-5.70%+7.44%+13.18%SAVACassava Sciences0.00%+31.14%+31.14%+65.19%-89.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRXChimerix 2.00Hold$8.53-0.08% DownsideCOLLCollegium Pharmaceutical 3.25Buy$42.3323.03% UpsideNATRNature's Sunshine Products 3.00Buy$20.5029.01% UpsideSAVACassava Sciences 2.00Hold$2.00-33.11% DownsideCurrent Analyst Ratings BreakdownLatest SAVA, COLL, NATR, and CMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025COLLCollegium PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/11/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$44.008/1/2025NATRNature's Sunshine ProductsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $22.00(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94COLLCollegium Pharmaceutical$631.45M1.72$12.33 per share2.79$7.10 per share4.85NATRNature's Sunshine Products$454.36M0.62$1.25 per share12.72$8.71 per share1.82SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/ACOLLCollegium Pharmaceutical$69.19M$1.0433.095.72N/A5.13%97.28%13.87%11/6/2025 (Estimated)NATRNature's Sunshine Products$7.70M$0.7421.47∞N/A3.06%10.19%6.71%11/6/2025 (Estimated)SAVACassava Sciences-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/6/2025 (Estimated)Latest SAVA, COLL, NATR, and CMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SAVACassava SciencesN/A-$0.18N/A-$0.92N/AN/A7/31/2025Q2 2025NATRNature's Sunshine Products$0.1650$0.35+$0.1850$0.28$113.10 million$114.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRXChimerixN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMRXChimerixN/A6.336.33COLLCollegium Pharmaceutical3.271.181.10NATRNature's Sunshine ProductsN/A2.271.35SAVACassava SciencesN/A2.432.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRXChimerix45.42%COLLCollegium PharmaceuticalN/ANATRNature's Sunshine Products79.40%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCMRXChimerix13.10%COLLCollegium Pharmaceutical2.51%NATRNature's Sunshine Products5.60%SAVACassava Sciences12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRXChimerix9093.80 million78.15 millionOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableNATRNature's Sunshine Products85017.64 million16.65 millionOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableSAVA, COLL, NATR, and CMRX HeadlinesRecent News About These CompaniesCassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program WithdrawalSeptember 27 at 1:27 PM | finance.yahoo.comInvestors Purchase High Volume of Cassava Sciences Call Options (NASDAQ:SAVA)September 26 at 2:29 AM | americanbankingnews.comCassava Sciences Target of Unusually High Options Trading (NASDAQ:SAVA)September 24, 2025 | marketbeat.comRichard Barry Buys 7,172 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 24, 2025 | insidertrades.comGoldman Sachs Group Inc. Boosts Stake in Cassava Sciences, Inc. $SAVASeptember 24, 2025 | marketbeat.comCassava Boss Buys Big As Stock CollapsesSeptember 23, 2025 | finance.yahoo.comRichard Barry Acquires 7,172 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 23, 2025 | marketbeat.comInsider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 47,308 Shares of StockSeptember 23, 2025 | insidertrades.comRichard Barry Buys 47,308 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 22, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) CEO Richard Barry Acquires 190,633 SharesSeptember 22, 2025 | marketbeat.comCassava Sciences Releases New Corporate PresentationSeptember 8, 2025 | tipranks.comGMT Capital Corp Takes $675,000 Position in Cassava Sciences, Inc. $SAVASeptember 1, 2025 | marketbeat.comCassava Technologies Unveils AI Factory for Africa, Powered by NVIDIA SupercomputersAugust 25, 2025 | thezimbabwemail.comTCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deCassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comGinkgo Bioworks Holdings Q2 Earnings PreviewAugust 6, 2025 | msn.comCassava Sciences Announces Positive Preclinical ResultsAugust 6, 2025 | theglobeandmail.comCassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related EpilepsyAugust 4, 2025 | globenewswire.comSAVA - Cassava Sciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?By Dan Schmidt | September 22, 2025SAVA, COLL, NATR, and CMRX Company DescriptionsChimerix NASDAQ:CMRXChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Collegium Pharmaceutical NASDAQ:COLL$34.41 -0.24 (-0.69%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$34.38 -0.02 (-0.07%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Nature's Sunshine Products NASDAQ:NATR$15.89 -0.35 (-2.16%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$15.89 0.00 (0.00%) As of 09/26/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Cassava Sciences NASDAQ:SAVA$2.99 -0.11 (-3.55%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$3.04 +0.05 (+1.84%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
